Address: Csorsz ut 49-51 H-1124 Budapest,Hungary
Tel: +36 1 577 8200
Web: http://www.astellas.com/worldwide.html
Astellas Pharma Europe the world’s 20 largest pharmaceutical company, belonging to 15 thousand employees worldwide Astellas Pharma Inc. subsidiary. As a young and forward-looking company Astellas aims to improve the quality of life for people around the world, innovative and reliable pharmaceutical products, by providing products.
In 2005, Yamanouchi and Fujisawa merger created Astellas remains committed to the class of the first (‘first-in-class’), and class best (‘best-in-class’) products developed for the key therapeutic areas by combining high R & D and marketing opportunities in the pharmaceutical world market continued growth.
In October 2006, Astellas has launched a company called Vision 2015 management strategy. Declared goal is to világelsőkké within that category (GAL) to become a number of therapeutic areas where further innovation of the patients currently unmet needs can be met. The company’s vision is an integral part in 2008, launched a wide-ranging Changing TOMORROW ™ (‘Change your tomorrow’) campaign, which displays the company’s ability to create a brighter future stakeholders, especially patients.
Significant, ongoing investments in research and development will further strengthen research-based Astellas pharmaceutical company capacity by providing effective medicines for patients worldwide, and continues to doctors and trusted partner of network deployment.
In Europe the main strengths of the Astella organ transplantation, urology, dermatology and anti-infective agents and the therapeutic areas of pain prevail. In addition, Astellas aims to develop a gyógyszerportfóliót the needs of cancer patients.
Astellas Pharma Europe Ltd. is based in Staines near London, and operates sales subsidiaries throughout Europe and the CIS states and South Africa. Astellas Pharma International, as well as licensors and distributors, the company responsible for the Middle East and Africa sales as well.
Geninax® : an oral new-type quinolone antibacterial agent
Celecox® : the selective COX-2 lnhibitor
Lipitor® : a treatment for hypercholesterolemia
Micardis® : a treatment for hypertension
Gaster® : a treatment for peptic ulcers and gastritis
Luvox® : an antidepressant
Myslee® : a hypnotic
Cefzon® : an oral cephalosporin
Seroquel® : an antipsychotic agent
Dorner® : a treatment for chronic arterial occlusion
Nasea® : a 5-HT3 (receptor) antagonist
Targocid® : a glycopeptide antibiotic
MD Pál Szamosújvari, Judit Jávor, Pál Szamosújvari Jr—Founder, R&D Director, and Director of Pharma Patent respectively—share their insights on the activities of the company, the importance of R&D, the challenges…
Csilla Léka, general manager of Global Clinical Trials in Hungary shares her insights on the portfolio of the company, the most prevalent therapeutic areas, the developments in clinical trials over…
Calin Galaseanu, recently appointed general manager of Novo Nordisk Hungary, elaborates on the country’s strong treatment paradigm for diabetes. He goes on to highlight Hungary’s key positioning as a strategic…
László Dene, managing director of Bellis, gives his insights on the trends affecting the wholesale supply chain and product delivery in Hungary, the strategic positioning of the company as the…
Gergely Jánoki CEO of Medi-Radiopharma shares his insights on the activities of the company, the trends in the radiopharmaceutical industry while highlighting regulatory trends, the importance of quality, the driving…
Dr Antal Feller, CEO of Hungaropharma, gives his insights on the pharma trends affecting the wholesale supply chain and product delivery in Hungary, the strategic positioning of the company, on…
Francesco Banchi, general manager of Boehringer Ingelheim Hungary, elaborates on the successful development of the affiliate in recent years, making progress in new product reimbursement. As an experienced leader in…
Dr. Bodoky Gyorgy, founder and Honorary President of the Hungarian Society of Clinical Oncology (MKOT), explains the activities of the society, the multi-stakeholder collaborations MKOT has, the challenges of oncological…
Péter Ferdinandy and Zsuzsanna Helyes, President and Secretary General of the Hungarian Society for Experimental and Clinical Pharmacology (HUPHAR), share their insights about the role of the society, the R&D…
József Béres, President of Béres and Ferenc Major, CEO, share their insights on the history of the company, its performance and approach to creating brand awareness, the importance of R&D…
Dr. András Szabó, CEO of Szinapszis, a Hungarian market research and consulting agency specialized in the health industry, offers his expert insights on the key challenges and trends shaping the…
After years of planning and collaboration with various stakeholders, in 2017 the Hungarian government launched the Electronic Health Service Area (EESZT): a centralized database of patient records and health interventions…
See our Cookie Privacy Policy Here
